0 CHECKOUT

Ulcerative Colitis - Pipeline Review, H1 2015

  • ID: 3099730
  • January 2015
  • Region: Global
  • 359 pages
  • Global Markets Direct
1 of 4
Review Key Players Involved in Therapeutics Development for Ulcerative Colitis and See Their Major and Minor Projects

FEATURED COMPANIES

  • AlphaMab Co., Ltd
  • Biocon Limited
  • Effimune SAS
  • GT Biologics Limited
  • LTT Bio-Pharma Co., Ltd.
  • Receptos, Inc.
  • MORE

This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergo periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AlphaMab Co., Ltd
  • Biocon Limited
  • Effimune SAS
  • GT Biologics Limited
  • LTT Bio-Pharma Co., Ltd.
  • Receptos, Inc.
  • MORE

Introduction

Ulcerative Colitis Overview
Therapeutics Development
Pipeline Products for Ulcerative Colitis - Overview
Pipeline Products for Ulcerative Colitis - Comparative Analysis
Ulcerative Colitis - Therapeutics under Development by Companies
Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes
Ulcerative Colitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Ulcerative Colitis - Products under Development by Companies
Ulcerative Colitis - Products under Investigation by Universities/Institutes

Ulcerative Colitis - Companies Involved in Therapeutics Development
Ajinomoto Pharmaceuticals Co., Ltd.
AlphaMab Co., Ltd
Altheus Therapeutics, Inc.
Am-Pharma B.V.
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Athersys, Inc.
Atlantic Healthcare plc
Avaxia Biologics, Inc.
Biocon Limited
BioLineRx, Ltd.
Bristol-Myers Squibb Company
Celgene Corporation
Cellceutix Corporation
Celltrion, Inc.
ChemoCentryx, Inc.
ChironWells GmbH
Cosmo Pharmaceuticals S.p.A
Dr. Falk Pharma GmbH
Drais Pharmaceuticals, Inc.
Effimune SAS
Emergent BioSolutions Inc.
Enceladus Pharmaceuticals BV
Epirus Biopharmaceuticals, Inc.
Euroscreen S.A.
Farmacija d.o.o. Tuzla
Flexion Therapeutics, Inc.
Galapagos NV
Genentech, Inc.
Genfit SA
Genor BioPharma Co., Ltd.
Gilead Sciences, Inc.
GT Biologics Limited
GW Pharmaceuticals plc
iCo Therapeutics Inc.
InDex Pharmaceuticals AB
INOXIA Lifesciences GmbH
Invion Limited
Johnson & Johnson
Kaken Pharmaceutical Co., Ltd.
LIPID THERAPEUTICS GmbH
LTT Bio-Pharma Co., Ltd.
Mabion SA
Medestea Research & Production S.p.A.
Morphotek, Inc.
Nogra Pharma Limited
Oncobiologics, Inc.
Pfizer Inc.
Pluristem Therapeutics Inc.
ProtAb Ltd
Qu Biologics Inc.
Receptos, Inc.
Sandoz Inc.
Sanofi
Sigmoid Pharma Limited
Stelic Institute & Co.
sterna biologicals Gmbh & Co KG
Synergy Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
TiGenix NV
Tillotts Pharma AG
Trino Therapeutics Ltd
Vascular Biogenics Ltd.
Ventria Bioscience
Zyngenia, Inc.

Ulcerative Colitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles
(mesalamine + N-acetylcysteine) - Drug Profile
(metenkefalin + tridecactide) - Drug Profile
AB-0045 - Drug Profile
abrilumab - Drug Profile
ABS-11 - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
AJM-300 - Drug Profile
alicaforsen sodium - Drug Profile
Anatabine - Drug Profile
apremilast - Drug Profile
ASP-3291 - Drug Profile
AVX-470 - Drug Profile
AW/EPO-002 - Drug Profile
AW/EPO-003 - Drug Profile
AW/EPOPD-01 - Drug Profile
AW/EPOPD-02 - Drug Profile
AW/EPOPD-06 - Drug Profile
bertilimumab - Drug Profile
BL-7040 - Drug Profile
BLI-1006 - Drug Profile
brilacidin - Drug Profile
budesonide - Drug Profile
budesonide ER - Drug Profile
budesonide ER - Drug Profile
CCX-507 - Drug Profile

Cell Therapy for Ulcerative Colitis and Inflammatory Bowel Disease - Drug Profile
CNDO-201 - Drug Profile
Cx-602 - Drug Profile
cyclosporine CR - Drug Profile
DIMS-0150 - Drug Profile
Drugs for Ulcerative Colitis - Drug Profile
eldelumab - Drug Profile
enalaprilat - Drug Profile
ES-210 - Drug Profile
ESN-282 - Drug Profile
etrolizumab - Drug Profile
FX-003 - Drug Profile
GED-0507 - Drug Profile
GFT-505 - Drug Profile
GLPG-0974 - Drug Profile
GLPG-1205 - Drug Profile
GS-5745 - Drug Profile
GWP-42003 - Drug Profile
hyaluronate sodium - Drug Profile
IAC VITA - Drug Profile
infliximab - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
INV-103 - Drug Profile
INV-88 - Drug Profile
KAG-308 - Drug Profile
KANAb-071 - Drug Profile
Leukothera - Drug Profile
Low Molecular Weight Heparin - Drug Profile
LT-0011 - Drug Profile
LT-02 - Drug Profile
MD-707 - Drug Profile
mesalamine - Drug Profile
mesalamine - Drug Profile
mesalamine CR - Drug Profile
mesalamine ER - Drug Profile
Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn's Disease - Drug Profile
Monoclonal Antibodies to Inhibit TNFR25 for Gastrointestinal Disorders and Asthma - Drug Profile
Monoclonal Antibody to Inhibit Ang-2 and TNF-a for Ulcerative Colitis, Arthritis and Inflammatory Disease - Drug Profile
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and

Cardiovascular Diseases - Drug Profile
MultiStem - Drug Profile
naltrexone - Drug Profile
Nanocort - Drug Profile
peficitinib - Drug Profile
Peptides to Inhibit IL-1 Beta for Ulcerative Colitis and Crohn's Disease - Drug Profile
PF-00547659 - Drug Profile
PH-44 - Drug Profile
PH-46A - Drug Profile
PH-5 - Drug Profile
Prozumab - Drug Profile
QBECO - Drug Profile

Recombinant Human Alkaline Phosphatase - Drug Profile
Rosburix - Drug Profile
RPC-1063 - Drug Profile
SAR-252067 - Drug Profile
SB-012 - Drug Profile
SD-010 - Drug Profile
Small Molecule for Ulcerative Colitis and Inflammation - Drug Profile
Small Molecule to Agonize OP3 Receptor for Crohn's Disease and Ulcerative Colitis - Drug Profile
Small Molecules for Gastrointestinal Disorders - Drug Profile
Small Molecules to Inhibit IL-13 for Ulcerative Colitis - Drug Profile
Small Molecules to Target IL-13 for Ulcerative Colitis - Drug Profile
SP-333 - Drug Profile

Stem Cell Therapy for Inflammatory Bowel Disease - Drug Profile
STNM-01 - Drug Profile
TAK-114 - Drug Profile
tofacitinib - Drug Profile
TP-10 - Drug Profile
VB-201 - Drug Profile
VEDA-1209 - Drug Profile
vedolizumab - Drug Profile
VEN-120 - Drug Profile
Ulcerative Colitis - Recent Pipeline Updates
Ulcerative Colitis - Dormant Projects
Ulcerative Colitis - Discontinued Products
Ulcerative Colitis - Product Development Milestones
Featured News & Press Releases

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Ulcerative Colitis, H1 2015
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2015
Ulcerative Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2015
Ulcerative Colitis - Pipeline by AlphaMab Co., Ltd, H1 2015
Ulcerative Colitis - Pipeline by Altheus Therapeutics, Inc., H1 2015
Ulcerative Colitis - Pipeline by Am-Pharma B.V., H1 2015
Ulcerative Colitis - Pipeline by Amgen Inc., H1 2015
Ulcerative Colitis - Pipeline by Astellas Pharma Inc., H1 2015
Ulcerative Colitis - Pipeline by AstraZeneca PLC, H1 2015
Ulcerative Colitis - Pipeline by Athersys, Inc., H1 2015
Ulcerative Colitis - Pipeline by Atlantic Healthcare plc, H1 2015
Ulcerative Colitis - Pipeline by Avaxia Biologics, Inc., H1 2015
Ulcerative Colitis - Pipeline by Biocon Limited, H1 2015
Ulcerative Colitis - Pipeline by BioLineRx, Ltd., H1 2015
Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Company, H1 2015
Ulcerative Colitis - Pipeline by Celgene Corporation, H1 2015
Ulcerative Colitis - Pipeline by Cellceutix Corporation, H1 2015
Ulcerative Colitis - Pipeline by Celltrion, Inc., H1 2015
Ulcerative Colitis - Pipeline by ChemoCentryx, Inc., H1 2015
Ulcerative Colitis - Pipeline by ChironWells GmbH, H1 2015
Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2015
Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2015
Ulcerative Colitis - Pipeline by Drais Pharmaceuticals, Inc., H1 2015
Ulcerative Colitis - Pipeline by Effimune SAS, H1 2015
Ulcerative Colitis - Pipeline by Emergent BioSolutions Inc., H1 2015
Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H1 2015
Ulcerative Colitis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Ulcerative Colitis - Pipeline by Euroscreen S.A., H1 2015
Ulcerative Colitis - Pipeline by Farmacija d.o.o. Tuzla, H1 2015
Ulcerative Colitis - Pipeline by Flexion Therapeutics, Inc., H1 2015
Ulcerative Colitis - Pipeline by Galapagos NV, H1 2015
Ulcerative Colitis - Pipeline by Genentech, Inc., H1 2015
Ulcerative Colitis - Pipeline by Genfit SA, H1 2015
Ulcerative Colitis - Pipeline by Genor BioPharma Co., Ltd., H1 2015
Ulcerative Colitis - Pipeline by Gilead Sciences, Inc., H1 2015
Ulcerative Colitis - Pipeline by GT Biologics Limited, H1 2015
Ulcerative Colitis - Pipeline by GW Pharmaceuticals plc, H1 2015
Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H1 2015
Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H1 2015
Ulcerative Colitis - Pipeline by INOXIA Lifesciences GmbH, H1 2015
Ulcerative Colitis - Pipeline by Invion Limited, H1 2015
Ulcerative Colitis - Pipeline by Johnson & Johnson, H1 2015
Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2015
Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H1 2015
Ulcerative Colitis - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015
Ulcerative Colitis - Pipeline by Mabion SA, H1 2015
Ulcerative Colitis - Pipeline by Medestea Research & Production S.p.A., H1 2015
Ulcerative Colitis - Pipeline by Morphotek, Inc., H1 2015
Ulcerative Colitis - Pipeline by Nogra Pharma Limited, H1 2015
Ulcerative Colitis - Pipeline by Oncobiologics, Inc., H1 2015
Ulcerative Colitis - Pipeline by Pfizer Inc., H1 2015
Ulcerative Colitis - Pipeline by Pluristem Therapeutics Inc., H1 2015
Ulcerative Colitis - Pipeline by ProtAb Ltd, H1 2015
Ulcerative Colitis - Pipeline by Qu Biologics Inc., H1 2015
Ulcerative Colitis - Pipeline by Receptos, Inc., H1 2015
Ulcerative Colitis - Pipeline by Sandoz Inc., H1 2015
Ulcerative Colitis - Pipeline by Sanofi, H1 2015
Ulcerative Colitis - Pipeline by Sigmoid Pharma Limited, H1 2015
Ulcerative Colitis - Pipeline by Stelic Institute & Co., H1 2015
Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2015
Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals, Inc., H1 2015
Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Ulcerative Colitis - Pipeline by TiGenix NV, H1 2015
Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H1 2015
Ulcerative Colitis - Pipeline by Trino Therapeutics Ltd, H1 2015
Ulcerative Colitis - Pipeline by Vascular Biogenics Ltd., H1 2015
Ulcerative Colitis - Pipeline by Ventria Bioscience, H1 2015
Ulcerative Colitis - Pipeline by Zyngenia, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Ulcerative Colitis Therapeutics - Recent Pipeline Updates, H1 2015
Ulcerative Colitis - Dormant Projects, H1 2015
Ulcerative Colitis - Discontinued Products, H1 2015
Ulcerative Colitis - Discontinued Products (Contd..1), H1 2015

List of Figures

Number of Products under Development for Ulcerative Colitis, H1 2015
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- Ajinomoto Pharmaceuticals Co., Ltd.
- AlphaMab Co., Ltd
- Altheus Therapeutics, Inc.
- Am-Pharma B.V.
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Athersys, Inc.
- Atlantic Healthcare plc
- Avaxia Biologics, Inc.
- Biocon Limited
- BioLineRx, Ltd.
- Bristol-Myers Squibb Company
- Celgene Corporation
- Cellceutix Corporation
- Celltrion, Inc.
- ChemoCentryx, Inc.
- ChironWells GmbH
- Cosmo Pharmaceuticals S.p.A
- Dr. Falk Pharma GmbH
- Drais Pharmaceuticals, Inc.
- Effimune SAS
- Emergent BioSolutions Inc.
- Enceladus Pharmaceuticals BV
- Epirus Biopharmaceuticals, Inc.
- Euroscreen S.A.
- Farmacija d.o.o. Tuzla
- Flexion Therapeutics, Inc.
- Galapagos NV
- Genentech, Inc.
- Genfit SA
- Genor BioPharma Co., Ltd.
- Gilead Sciences, Inc.
- GT Biologics Limited
- GW Pharmaceuticals plc
- iCo Therapeutics Inc.
- InDex Pharmaceuticals AB
- INOXIA Lifesciences GmbH
- Invion Limited
- Johnson & Johnson
- Kaken Pharmaceutical Co., Ltd.
- LIPID THERAPEUTICS GmbH
- LTT Bio-Pharma Co., Ltd.
- Mabion SA
- Medestea Research & Production S.p.A.
- Morphotek, Inc.
- Nogra Pharma Limited
- Oncobiologics, Inc.
- Pfizer Inc.
- Pluristem Therapeutics Inc.
- ProtAb Ltd
- Qu Biologics Inc.
- Receptos, Inc.
- Sandoz Inc.
- Sanofi
- Sigmoid Pharma Limited
- Stelic Institute & Co.
- sterna biologicals Gmbh & Co KG
- Synergy Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- TiGenix NV
- Tillotts Pharma AG
- Trino Therapeutics Ltd
- Vascular Biogenics Ltd.
- Ventria Bioscience
- Zyngenia, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • Sanofi S.A.
  • Purdue Pharma L.P.
  • Almirall, S.A.